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P
rofessional societies and their journals 
are like universities in that they occupy 
a unique position in society. On the 
one hand, they are concerned with the 
advancement of knowledge and with spreading 
information to the widest possible audience. On 
the other, these activities require living in the real 
world, where we have to interact with govern-
ments and other nonprofi t enterprises, as well as 
commercial entities. We hope no one can ques-
tion that our ‘ivory tower’ function is benign and 
aims at the betterment of the lot of humankind. 
But dealing with powerful entities such as govern-
ments and corporations requires walking a fi ne 
line; compromise is a necessary condition of any 
complex social interaction. We have to keep our 
primary mission in clear focus while we partici-
pate in ‘compromising’ activities.
Nowhere is this problem more acute than in the 
issue of accepting advertising for drugs in journals 
such as Kidney International. A signifi cant fraction 
of the International Society of Nephrology’s (ISN’s) 
budget comes from advertising in the journal by 
pharmaceutical companies, as well as their support 
for our meetings. Th e ISN uses these monies to 
conduct its global activities in education and pre-
vention. Taking from the rich to give to the poor 
is a time-honored activity of charitable organiza-
tions. But, unlike with unadulterated charity, the 
rich here need something in return: access to the 
‘gatekeepers’ of drug prescriptions. Advertising is 
a fact of life in scientifi c publications, and we tried 
to arrive at a modus vivendi that allows us to walk 
an ethically defensible path.
Let us start with the question of whether adver-
tising works. I have always been surprised by the 
size of advertising budgets, and the sums that cor-
porations pay for advertisements that seem to be 
‘fi llers’ in journals such as ours. Obviously, I have 
been suff ering from the delusion that advertising 
does not work; it does not work on me (I say pat-
ting myself on the back). Th ese naive considera-
tions, which I assure you are common, need to be 
refracted through the lens of reality. Let us exam-
ine the characteristics of the people who pay for 
advertising. Numerous studies have shown that 
the best and brightest students have been enter-
ing the fi eld of business studies since the end of 
the 1960s. A simple respect for their intelligence 
should force one to suspect that the massive 
advertising budgets of pharmaceutical compa-
nies must lead to greater sales;  the pharmaceuti-
cal industry has the highest budget on a per unit 
basis as compared with other advertisers.
Economists have always argued about the 
mechanism by which advertising works.1 On the 
one hand, it has been postulated that advertising 
provides new information, allowing the consumer 
to choose the ‘appropriate’ product. Another 
school proposes that promotion leads to infor-
mational confusion, allowing the development 
of artifi cial product diff erentiation. While my 
knowledge of economics is too primitive to allow 
the distinction between these two models, they do 
smack of preconceived ideologies. One wonders 
whether the marketplace is too heterogeneous for 
one to make a uniform conclusion regarding all 
products. For instance, advertising for perfumes 
results in high prices, whereas advertising for 
hamburgers causes a decline in price. Advertis-
ing for prescription drugs is completely diff erent 
from these two examples. First, it is heavily regu-
lated by the government. Second, the continuing 
development of new drugs and their clear utility 
in the management of disease make the informa-
tional content of drug advertising a necessity for 
the consumer. But who is the consumer here? We 
would like to think that it is the prescribing physi-
cian. Detailed analysis of prescription practices 
demonstrates unequivocally that extensive adver-
tising leads to the excessive use of high-priced, 
heavily promoted brand names when other agents 
might be equally eff ective. Recently, the pharma-
ceutical industry has begun to advertise directly to 
the consumer, that is, the patient. Th e wild success 
of this practice initiated the conversion of Viagra 
from a drug with some medical indications into 
a performance-enhancing reagent that has raised 
a large number of ethical and medical issues yet 
to be resolved and that will likely backfi re on the 
industry as a whole. Th e United States Congress 
will soon hold open hearings on this practice.
Th e challenge for Kidney International is to 
balance our two needs, scholarly publication and 
fi nancial survival. How can we publish objective 
analysis of the eff ectiveness, or lack thereof, of 
drugs simultaneously with advertising that trum-
pets their utility in other sections of the journal? 
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How do we ascertain that the advertising is cor-
rect and not overblown? We now have a policy 
that all advertisements are reviewed by the editors 
for appropriateness. We also have some protection 
in the regulatory oversight of the pharmaceutical 
industry; each drug product advertisement must 
be accompanied by a Food and Drug Adminis-
tration-mandated product information page that 
describes the approved indications for the use of 
the drug, the dosages necessary, and, most impor-
tantly, the side eff ects. However, as we all know, 
this information is printed in a smaller font, and 
I doubt that many physicians read it.
Th e coin of the realm in advertising is access 
and visibility. Advertisers pay more for specifi c 
positions in the journal — the inside front cover, 
the back cover, the pages facing the table of con-
tents, and so on — and for their ads not to appear 
on a page facing a competitor’s ad. Th e place-
ment of the ads is determined by the fi nancial 
and design needs of the advertiser and journal. 
Th e mandated page requires us to have consecu-
tive ad pages, preferably facing each other. Th is 
rule sometimes determines where we can place 
the ads.
Everybody wants the most visible ads. In the 
15 October 2006 and 15 November 2006 issues, 
we ran a ‘tip-on’ ad, an ad glued to the cover of 
the journal, consisting of a picture of the cover 
with an advertisement below it. Th is ad gener-
ated angry comments from several readers, one 
of which is published in the Letters to the Edi-
tor section of this issue (page 952). While we do 
advertise using the tip-on format, this tip-on 
was mistakenly printed as large as the size of the 
journal and mistakenly mimicked the cover. It 
should have been smaller than the journal and 
should not have included the cover design, so 
that readers could clearly diff erentiate between 
the ad and the real cover. Th is was a production 
mistake on our part for which we apologize. It 
will not happen again. Another advertising for-
mat in question is that of the ‘belly band’ ad. Th is 
is a belt-like ad with dimensions smaller than 
the cover that wraps around the journal and is 
torn once the magazine is opened. Aft er much 
consultation with our publishers, the ISN, and 
the editorial staff , we decided that such an ad is 
benign and does not interfere with the content of 
the journal. However, we have limited the size of 
belly bands to ensure that they cover only a por-
tion of the cover image and no longer match the 
size of the cover image — again, to distinguish 
between content and advertising.
No serious pharmaceutical fi rm will publish 
wrong or misleading information, and certainly 
not in a professional journal. All drugs adver-
tised are benefi cial when used in the proper set-
ting. Th e major problem I fi nd in advertising is 
that while oft en a drug is not unique in its action, 
the goal of advertisers is to induce physicians to 
prescribe their drug in place of another similar 
or less expensive one; it is the issue of persuasion 
discussed by Leffl  er in his classic paper.1 Here, 
there is fundamentally no countervailing force 
to defend the advertising of a drug other than 
the objective evaluation provided by the scien-
tifi c literature.
Yet, if we support the use of a drug on the basis 
of a study in the literature, we have to assure the 
reader that the paper is objective and unbiased. 
How does one do that? One method is to acquaint 
the reader with the potential confl icts of inter-
est that the authors of the articles might have. 
In the past, we have required submitting authors 
to declare any confl ict of interest. Th e response 
has been as expected: few authors have declared 
such a confl ict. Needless to say, we have received 
several letters from readers pointing out potential 
confl icts of interest in our papers. Th e situation is 
made more acute when some of the best studies 
on the eff ects of certain drugs on one or another 
aspect of kidney disease are entirely funded by 
pharmaceutical companies. Further, most experts 
in clinical or pharmacological research have 
been tapped by the industry to supply informed 
opinion regarding the mechanism of action or 
use of drugs. Th ese issues raise some diffi  cult 
problems, which have been lumped under the 
unfortunate term ‘conflict of interest,’ whose 
use is problematic since most scientists feel that 
they can be objective and would not be swayed by 
these activities. We are developing a new policy 
similar to that of many other journals, such as 
the New England Journal of Medicine, wherein 
authors will be asked to disclose — rather than 
confl icts — any fi nancial relationships they have 
with pharmaceutical companies, such as lecture 
fees, consulting arrangements, and so on. Th is 
new policy will enable our reviewers, editors, 
and readers to understand the interests behind 
the research.
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